Market closed
Ventyx Biosciences/$VTYX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ventyx Biosciences
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
Ticker
$VTYX
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
81
Website
VTYX Metrics
BasicAdvanced
$104M
-
-$1.97
0.58
-
Price and volume
Market cap
$104M
Beta
0.58
52-week high
$8.67
52-week low
$1.34
Average daily volume
1M
Financial strength
Current ratio
17.973
Quick ratio
17.088
Long term debt to equity
3.835
Total debt to equity
4.249
Management effectiveness
Return on assets (TTM)
-33.48%
Return on equity (TTM)
-54.27%
Valuation
Price to book
0.41
Price to tangible book (TTM)
0.41
Price to free cash flow (TTM)
-0.763
Growth
Earnings per share change (TTM)
-40.13%
3-year earnings per share growth (CAGR)
-33.30%
What the Analysts think about VTYX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Ventyx Biosciences stock.
VTYX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
VTYX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
VTYX News
AllArticlesVideos
Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress
GlobeNewsWire·2 weeks ago
Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025
GlobeNewsWire·3 weeks ago
Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Ventyx Biosciences stock?
Ventyx Biosciences (VTYX) has a market cap of $104M as of March 14, 2025.
What is the P/E ratio for Ventyx Biosciences stock?
The price to earnings (P/E) ratio for Ventyx Biosciences (VTYX) stock is 0 as of March 14, 2025.
Does Ventyx Biosciences stock pay dividends?
No, Ventyx Biosciences (VTYX) stock does not pay dividends to its shareholders as of March 14, 2025.
When is the next Ventyx Biosciences dividend payment date?
Ventyx Biosciences (VTYX) stock does not pay dividends to its shareholders.
What is the beta indicator for Ventyx Biosciences?
Ventyx Biosciences (VTYX) has a beta rating of 0.58. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.